2014.11.12 R3 김재민 / Prof. 장영운 Journal conference 1.

Slides:



Advertisements
Similar presentations
Practice Guidelines & clinical pathway on management of Dyspepsia
Advertisements

Peptic ulcer.
BSG Guidelines Management of Dyspepsia
D YSPEPSIA & P EPTIC U LCER By Dr. Zahoor 1. D YSPEPSIA What is Dyspepsia ?  Dyspepsia is used to describe number of upper abdominal symptoms such as.
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
DYSPEPSIA Leena Patel 1/2/12. OVERVIEW Statistics Red flags Management H-pylori testing and treatment.
Comparative evaluation of conventional methods and Elisa based IgG antibodies detection for diagnosis of helicobacter pylori infection in cases of dyspepsia.
1 Clinical Pharmacy Chapter Eight Peptic ulcer disease Rowa’ Al-Ramahi.
Treatment of H Pylori -Peptic Ulcer Disease By Prof. Hanan Hagar Department of Physiology and Pharmacology.
An approach to dyspeptic patients
Peptic Ulcer Disease. Peptic ulcer  refers to erosion of the mucosa lining any portion of the G.I. tract.  It is defined as : A circumscribed ulceration.
Hilary Suzawa, MD Updated July 2013 by Anoop Agrawal, MD
Prevalence of Helicobacter pylori infection in chronic dyspeptic patients with peptic ulcer in Naresuan University Hospital Researchers Rutnumnoi Thanachat.
H PYLORI BY MARUF A.. Historical Background  Marshall and Warren identified and subsequently cultured the gastric bacterium, Campylobacter pyloridis,
ENDOSCOPIC FEATURES IN PATIENTS WITH MARGINAL ZONE LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) IN A FOLLOW UP OF 10 YEARS 1 N.V. Chrysanthos,
Gastric Acid Secretion 1. Acid synthesis – regulated by 3 transporters Lumen Plasma Parietal cell.
Helicobacter First one discovered in 1983 by Drs. Barry Marshall and J. Robin Warren Originally classified as a Campylobacter.
PUD Peptic Ulcer Disease Prince Sattam Bin AbdulAziz University College Of Pharmacy Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of.
BSG Guidelines Management of Dyspepsia By Matt Johnson.
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
D YSPEPSIA & P EPTIC U LCER By Dr. Zahoor 1. D YSPEPSIA What is Dyspepsia ?  Dyspepsia is used to describe number of upper abdominal symptoms such as.
LOGO Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-lable, randomised trial 杨 天 Epidemiology.
Peptic Ulcer Disease Dr. Wael H. Mansy, MD Assistant Professor College of Pharmacy King Saud University.
JOURNAL REVIEW Questionnaire study and audit of use of ACEI and monitoring in general practice BMJ 1999;318:
The ulcer of gastric stump: a case-control study Coordinators: Author: Roxana Spac Dr.Anca Negovan Drd. Monica Pantea Co-author: Dr Nina Sincu Andreea.
Update of TARGET ( T reatment a nd R elief of G astroint e s t inal disorder) DR NORITA YASMIN MORNING READ 19/9/13 1.
The Recurrence of Helicobacter pylori Infection: Incidence and Variables Influencing It. A Critical Review Ph.D. candidate: Tian-yi Wang Gisbert J P. The.
Dyspepsia Resident Teaching Rounds Steve Radke August 11, 2003 References: Ontario Program for Optimal Therapeutics, Ontario Guidelines for PUD and GERD.
What’s New in Helicobacter Pylori Therapy
H.Pylori and PUD Yousif A. Qari,MD,ABIM,FRCPC Cosultanat Gastroenterologist King Abdulaziz University Hospital Jeddah,Saudi Arabia.
CASTRIC ULCER CASE A 72-year-old male was seen by his physician because of epigastric distress shortly after eating a meal, and occasionally during the.
Peptic ulcer Presented by د. قصي العبيدي بورد ( دكتوراه ) جراحه عامه جامعة الكوفة - كلية طب.
The Perils of PPIs How can they harm us? What should they be used for?
CLINICAL INTEGRATION OCTOBER 27, 2009 PENAFLOR*QUINTO*RAMOS*SICAT* SUACO*TIO CUISON DIAGNOSTICS.
R3 정명화 /Prof. 장재영 Gastrointest. Endosc. 2012; 75:39-46.
소화기내과 R1. 임형석 / Pf. 김정욱. BACKGROUND Recent data showed that H. pylori infection is less common in patients with IBD The prevalence of IBD has been increasing.
Effect of Helicobacter pylori Eradication on Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasm Am J Gastroenterol 2014; 109:60–67.
1 Motohiko Kato, Tsutomu Nishida, Katsumi Yamamoto, Shiro Hayashi, Shinji Kitamura, Takamasa,Yabuta, Toshiyuki Yoshio, Takeshi Nakamura, Masato Komori,6.
Famotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions FOOK–HONG NG, SIU–YIN WONG, KWOK–FAI LAM,
Treatment algorithm – Limited stage Gastric Marginal Zone Lymphoma Diagnosis: – Histology including appropriate B-cell immunohistochemical panel and staining.
HELICOBACTER PYLORI Millions of years old microorganism of mankind Causes a spectrum of diseases Obviously requires high priority Treatment strategies.
The American Journal of Gastroenterology, October 2014, Volume 109:1595–1602 Prof. 장재영 /R3 김다래.
Helicobacter pylori and Gastric Lymphoma
Eradication of Helicobacter pylori After Endoscopic Resection of Gastric Tumors Does Not Reduce Incidence of Metachronous Gastric Carcinoma Clinical Gastroenterology.
Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dysplasia: an analysis using the Vienna classification R1 김진숙 / Prof. 장재영.
Clinical Practice Helicobacter pylori Infection Kenneth E.L. McColl, M.D. N Engl J Med Volume 362(17): April 29, 2010.
H. Pylori. Helicobacter Pylori History (Warren and Marshall) Antibiotic was used Subsequently, they isolated a bacteria Self-experiments (Marshal.
R3. 최태웅 / Pf. 장재영 Journal Conference ( ) Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review.
Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status : prospective endoscopic cohort.
KShotaro Nakamura,1 Toshiro Sugiyama,2 Takayuki Matsumoto,1 Katsunori Iijima,3 Shouko Ono,4 Masahiro Tajika,5 Akira Tari,6 Yasuhiko Kitadai,7 Hiroshi Matsumoto,8.
Epigastric pain severe enough to hospitalise patient Ulcerogenic medication, eg NSAIDs, aspirin Previous gastric ulcer Concomitant.
Department: Microbiology
Fatimah Abdullah 6th year MS, KFU
Helicobacter pylori eradication prior bariatric/metabolic surgery
Peptic ulcer disease-2 Clinical presentation & investigations
Molecular characterization and antibiotic resistance profiles of H
Dr. Abdullah Al Mdani Consultant G/I Hepatology
Dyspepsia & Peptic Ulcer
DR.IHSAN Edan. A. ALSAIMARY (Ph.D , assist professor)
Gastrointestinal pathogens: Helicobacter pylori
Dyspepsia & Peptic Ulcer
Lecture 11 Gastrointestinal Disorders Peptic Ulcer
Screening for H. Pylori – finding out if it prevents stomach cancer
Volume 137, Issue 5, Pages e2 (November 2009)
HELICOBACTER PYLORI INFECTION
Helicobacter pylori Eradication and Metachronous Gastric Cancer
ژورنال كلاب گوارش دكترقويدل دكترروحاني 8/4/96.
Care of Patients with Stomach Disorders
Eradication Therapy for Helicobacter pylori
Nicholas J. Talley, Nimish B. Vakil, Paul Moayyedi  Gastroenterology 
Presentation transcript:

R3 김재민 / Prof. 장영운 Journal conference 1

Helicobacter pylori : causative bacterium for gastric cancer The possible prophylactic effect of H. pylori eradication on the development of gastric cancer ? randomized controlled study in Japan (2008) : eradication therapy reduced the risk of developing metachronous gastric cancer after EMR of early gastric cancer INTRODUCTION INTRODUCTION 2

However, in people with H. pylori infection in whom the cancer is not yet established, a meta-analysis of randomized controlled trials failed to show a significant prophylactic effect of eradication therapy Recently, analysis of extended follow-up of the original RCT which was included in the meta-analysis, : significant reduction of gastric cancer incidence 14.7 years after the eradication therapy INTRODUCTION INTRODUCTION 3

We showed : eradication of H. pylori in patients with peptic ulcer disease reduced their risk of developing gastric cancer one-third after a f/u period as long as 8.6 years (mean, 3.4 years) We have now followed our cohort for as long as 17.4 years INTRODUCTION INTRODUCTION 4

PATIENTS and METHODS PATIENTS and METHODS patients (152 women and 1190 men) with PUD, received H.pylori eradication therapy mean age : 50 years (17~83 years) ~ underwent endoscopy at enrollment to evaluate PUD 776 had GU, 495 had DU, 71 had both Excluded previous gastrectomy or EMR for gastric neoplasm pregnant allergic to penicillin, clarithromycin, or metronidazole taking anticoagulants

Eradication therapy and Eradication therapy and Post-eradication schedule Post-eradication schedule 6 H. pylori infection : culture(+) from endoscopic biopsy specimens Eradication therapy : PPI + amoxicillin or PPI + 2 of 3(amoxicillin, clarithromycin, or metronidazole) 1~2 months after completion of therapy : 13 C-urea breath test and endoscopy cure : culture(-) & rapid urease test(-) & UBT(-) endoscopy and UBT, yearly f/u until 2008

7 RESULTS RESULTS 21/1,030 Fail to 1 year f/u Total 1,222 f/u /1,2229/192 Fail to 1 year f/u

8 RESULTS RESULTS > > <

9

10 Retreatment & cured 포함

11 RESULTS RESULTS

CONCLUSIONS CONCLUSIONS A prophylactic effect for gastric cancer persists for more than 10 years after H.pylori eradication therapy, but we should be aware that cancer can develop even after that interval. 12